Introduction：Basic information about CAS 152923-56-3|Dacliximab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dacliximab |
|---|
| CAS Number | 152923-56-3 | Molecular Weight | / |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | / | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
Dacliximab BiologicalActivity
| Description | Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research[1]. |
|---|
| Related Catalog | Signaling Pathways >>Immunology/Inflammation >>Interleukin RelatedResearch Areas >>Inflammation/Immunology |
|---|
| References | [1]. Stanley L Cohan, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18. |
|---|
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
